Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

[Reliability of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 expression in breast cancer evaluated by immunohistochemistry].

Gu CS, Ying M, He YJ, Liu YQ, Dong B, Ouyang T, Lu AP.

Zhonghua Yi Xue Za Zhi. 2013 Aug 27;93(32):2571-3. Chinese.

PMID:
24351599
2.

Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).

Słodkowska J, Filas V, Buszkiewicz E, Trzeciak P, Wojciechowski M, Koktysz R, Staniszewski W, Breborowicz J, Rojo MG.

Folia Histochem Cytobiol. 2010 Jan 1;48(1):19-25. doi: 10.2478/v10042-010-0015-1.

3.

[Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].

Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.

Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):520-5. Chinese.

PMID:
21029696
4.

[Differences and clinical significance of receptor expression between primary and locally recurrent breast tumor tissues].

Ma XM, Han YW, Zhang J, Cui WJ, Wang X.

Zhonghua Zhong Liu Za Zhi. 2013 May;35(5):372-6. doi: 10.3760/cma.j.issn.0253-3766.2013.05.011. Chinese.

PMID:
24054015
5.

[Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer].

Wang B, Guan ZZ, Liu DG, Lin TY, Zhang L, Xia ZJ, Teng XY.

Ai Zheng. 2004 Dec;23(12):1710-3. Chinese.

PMID:
15601567
7.
8.

Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.

Brouckaert O, Pintens S, Van Belle V, Van Huffel S, Camerlynck E, Amant F, Leunen K, Smeets A, Berteloot P, Van Limbergen E, Decock J, Hendrickx W, Weltens C, Van den Bogaert W, Vanden Bempt I, Drijkoningen M, Paridaens R, Wildiers H, Vergote I, Christiaens MR, Neven P.

Breast Cancer Res Treat. 2009 May;115(2):349-58. doi: 10.1007/s10549-008-0110-6. Epub 2008 Jul 16.

PMID:
18629635
10.

Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.

Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR.

J Clin Oncol. 2008 May 10;26(14):2373-8. doi: 10.1200/JCO.2007.14.4287. Epub 2008 Apr 14. Erratum in: J Clin Oncol. 2008 Jun;26(18):3110.

11.

Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.

Sutela A, Vanninen R, Sudah M, Berg M, Kiviniemi V, Rummukainen J, Kataja V, Kärjä V.

Acta Oncol. 2008;47(1):38-46.

PMID:
17851859
12.

Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.

Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O'Malley FP, Miller N, Andrulis IL, Brenner DM, Clemons MJ.

Anticancer Res. 2009 May;29(5):1557-62.

13.

Expressions of ER, PR, HER-2, COX-2, and VEGF in primary and relapsed/metastatic breast cancers.

Sun L, Yu DH, Sun SY, Zhuo SC, Cao SS, Wei L.

Cell Biochem Biophys. 2014 Apr;68(3):511-6. doi: 10.1007/s12013-013-9729-y.

PMID:
23955549
14.
15.
16.

Positron emission mammography: correlation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status and 18F-FDG.

Wang CL, MacDonald LR, Rogers JV, Aravkin A, Haseley DR, Beatty JD.

AJR Am J Roentgenol. 2011 Aug;197(2):W247-55. doi: 10.2214/AJR.11.6478.

PMID:
21785049
17.

Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L, Bergh J.

J Clin Oncol. 2012 Jul 20;30(21):2601-8. doi: 10.1200/JCO.2011.37.2482. Epub 2012 Jun 18.

18.

Breast cancer subtypes identified by the ER, PR and HER-2 status in Thai women.

Chuthapisith S, Permsapaya W, Warnnissorn M, Akewanlop C, Sirivatanauksorn V, Prasarttong Osoth P.

Asian Pac J Cancer Prev. 2012;13(2):459-62.

20.

Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.

Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Vergote I, Christiaens MR.

J Clin Pathol. 2005 Jun;58(6):611-6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk